British journal of pharmacology
Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S Menge, Florian J G Waleczek, Jonas A Haas, Anselm A Derda
Published: 202510.1111/bph.70247
Abstract
BACKGROUND AND PURPOSE: Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use…
Preview only. Read the full abstract at the source